NCT06720766Completed
Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity. However, there are still considerable uncertainties regarding the potential influence of confounding factors and the optimal application of cut-off values for obesity. The goal of this observational study is to learn about the optimal application of cut-off values of for Chinese people with obesity.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 565 (actual)
- First submitted
- 27 Nov 2024
- Start date
- 24 Oct 2023
- Primary completion date
- 30 Sept 2025
- Lead sponsor
- The Third People's Hospital of Chengdu
- Diseases
- Obesity, Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06720766
What you commit to
- Study type: Observational
- Participants enrolled: 565
- From 24 Oct 2023 to the primary completion date, 30 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have undergone liver transplantation
Other illness
- Patients with cardiac failure and/or significant valvular disease
- Patients with a confirmed diagnosis of active malignancy, or other terminal disease
Other
- Patients with ascites or pregnant women
- Patients with any active implantable medical device (such as a pacemaker or defibrillator)
- Patients with haemochromatosis
- Patients who have refused to undergo LB or blood tests
- Patients participating in another clinical trial within the preceding 30 days
Who the study is looking for
- Patients aged 18 years or older who provided written informed consent
- Patients who schedule to undergo bariatric surgery and a liver biopsy (LB) for the investigation of suspected MASLD
- Patients who schedule to undergo FibroScan examination
Age in the registry: 18 years to 70 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Third People's Hospital of Chengdu Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.